ReviewInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2014
Human metapneumovirus: review of an important respiratory pathogen.
Review in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 148 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
148 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study.The Lancet. Global health · 2021Pooled it
- Trial
- Accuracy of comprehensive PCR analysis of nasopharyngeal and oropharyngeal swabs for CT-scan-confirmed pneumonia in elderly patients: a prospective cohort study.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2019Trial
- Development and Validation of a Nomogram for Predicting Severe Respiratory Illness in Children with Isolated Human Metapneumovirus Infection.Children (Basel, Switzerland) · 2026Article
- Target-Based Antiviral Drug Development Against Human Respiratory Viruses.Pathogens (Basel, Switzerland) · 2026Review
- Stabilization of prefusion hMPV F improves manufacturability and protective immunity across hMPV lineages.Virologica Sinica · 2026Article
- Awareness of human metapneumovirus (hMPV) among healthcare professionals in Libya.The Journal of the Egyptian Public Health Association · 2026Article
- Article
- Two Cases of Diffuse Alveolar Haemorrhage Attributable to Human Metapneumovirus Infection: A Case Report.Respirology case reports · 2026Article
- Burden of Human Metapneumovirus in India: Epidemiological Trends and Clinical Impact.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine · 2026Review
- Machine learning and molecular modeling reveal potential inhibitors of the human metapneumovirus fusion protein.Molecular diversity · 2026Article
- Mechanistic insights and emerging applications of human metapneumovirus (HMPV) treatment: From molecular design to translational immunity.Folia microbiologica · 2026Review
- A Review of Respiratory Infection Caused by the Human Metapneumovirus: Occurrence, Epidemiology, Pathogenesis, Public Health Outcomes, and Intervention Strategies.Health science reports · 2026Article
- Resurgence of human metapneumovirus: an overview of past and current trends.Archives of microbiology · 2026Review
- Resurgence of human metapneumovirus: an overview of past and current trends.Archives of microbiology · 2026Review
- Article
- Genetic and epidemiological characteristics of the spread of human metapneumovirus in Bulgaria, 2023-2025.Frontiers in public health · 2026Article
- Forging a global shield against HMPV: Uniting healthcare systems and community action to counter a silent respiratory epidemic.AIMS public health · 2026Review
- Rational design and in silico characterization of a multiepitope mRNA vaccine candidate against human metapneumovirus (hMPV) using reverse vaccinology and immunoinformatics approaches.Scientific reports · 2025Article
- Designing a multi-epitope mRNA vaccine to combat human metapneumovirus based on consensus sequence using reverse vaccinology.Journal of computer-aided molecular design · 2025Article
88 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human metapneumovirus (hMPV), discovered in 2001, most commonly causes upper and lower respiratory tract infections in young children, but is also a concern for elderly subjects and immune-compromised patients. hMPV is the major etiological agent responsible for about 5% to 10% of hospitalizations of children suffering from acute respiratory tract infections. hMPV infection can cause severe bronchiolitis and pneumonia in children, and its symptoms are indistinguishable from those caused by human respiratory syncytial virus. Initial infection with hMPV usually occurs during early childhood, but re-infections are common throughout life. Due to the slow growth of the virus in cell culture, molecular methods (such as reverse transcriptase PCR (RT-PCR)) are the preferred diagnostic modality for detecting hMPV. A few vaccine candidates have been shown to be effective in preventing clinical disease, but none are yet commercially available. Our understanding of hMPV has undergone major changes in recent years and in this article we will review the currently available information on the molecular biology and epidemiology of hMPV. We will also review the current therapeutic interventions and strategies being used to control hMPV infection, with an emphasis on possible approaches that could be used to develop an effective vaccine against hMPV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.